Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Pimodivir Concept Formulations
NCT02659735Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimodivir in Influenza A virus infection (IAV) (10 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 1, Time to Reach Maximum Observed Plasma Concentration at Day 1 and 4 more. Started Dec 2015; status: completed.
02
Drugs
pimodivir
03
Conditions
Influenza A virus infection (IAV)
Beyond the preview
Go deeper on NCT02659735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659735.